blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3034512

EP3034512 - A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.10.2018
Database last updated on 16.07.2024
FormerThe patent has been granted
Status updated on  03.11.2017
FormerGrant of patent is intended
Status updated on  18.06.2017
FormerExamination is in progress
Status updated on  03.03.2017
Most recent event   Tooltip12.10.2018No opposition filed within time limitpublished on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Tseti, Ioulia
13 Pavlou Mela Street
145 61 Kifissia Attikis / GR
[2017/49]
Former [2016/25]For all designated states
Tseti, Ioulia
13 Pavlou Mela Street
145 61 Kifissia Attikis / GR
Inventor(s)01 / see applicant
...
 [2016/25]
Representative(s)Wibbelmann, Jobst
Wuesthoff & Wuesthoff
Patentanwälte und Rechtsanwalt PartG mbB
Schweigerstrasse 2
81541 München / DE
[N/P]
Former [2016/25]Wibbelmann, Jobst
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstrasse 2
81541 München / DE
Application number, filing date14386034.419.12.2014
[2016/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3034512
Date:22.06.2016
Language:EN
[2016/25]
Type: B1 Patent specification 
No.:EP3034512
Date:06.12.2017
Language:EN
[2017/49]
Search report(s)(Supplementary) European search report - dispatched on:EP13.03.2015
ClassificationIPC:C07K14/47
[2016/25]
CPC:
C07K14/4732 (EP,EA,IL,US); A61K47/64 (EA,US); A61K33/26 (EA,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/39]
Former [2016/25]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:Verfahren zur Herstellung von Eisen (III)-Casein-N-Acetyl-aspartylierten Komplexen und Verwendung derselben in pharmazeutischen Zusammensetzungen[2017/49]
English:A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions[2016/25]
French:Procédé de production de complexes fer (III) de la caséine N-acétyl-aspartyl et leur utilisation dans des compositions pharmaceutiques[2016/25]
Former [2016/25]Verfahren zur Herstellung von (III)-Kasein-n-acetyl-aspartylierten Komplexen und Verwendung davon in pharmazeutischen Zusammensetzungen
Examination procedure12.08.2016Amendment by applicant (claims and/or description)
12.08.2016Examination requested  [2016/39]
02.03.2017Despatch of a communication from the examining division (Time limit: M04)
06.04.2017Reply to a communication from the examining division
19.06.2017Communication of intention to grant the patent
18.10.2017Fee for grant paid
18.10.2017Fee for publishing/printing paid
18.10.2017Receipt of the translation of the claim(s)
Opposition(s)07.09.2018No opposition filed within time limit [2018/46]
Fees paidRenewal fee
20.12.2016Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XD]EP0243322  (MAGIS FARMACEUTICI [IT]) [XD] 6 * the whole document, in particular the claims *;
 [XD]WO2006021843  (BIOFER SPA [IT], et al) [XD] 6 * the whole document, in particular p. 4, Example 2 and claims 6-10 *;
 [AD]  - LAZZARI FLAVIO ET AL, "Overview of clinical trials in the treatment of iron deficiency with iron-acetyl-aspartylated casein", CLINICAL DRUG INVESTIGATION, (2005), vol. 25, no. 11, ISSN 1173-2563, pages 679 - 689, XP009182971 [AD] 1-6 * the whole document *

DOI:   http://dx.doi.org/10.2165/00044011-200525110-00001
 [AD]  - BURON ET AL, "On the racemisation of aspartic anhydride during its preparation", TETRAHEDRON ASYMMETRY, PERGAMON PRESS LTD, OXFORD, GB, (20070717), vol. 18, no. 13, doi:10.1016/J.TETASY.2007.07.003, ISSN 0957-4166, pages 1625 - 1627, XP022181932 [AD] 1-6

DOI:   http://dx.doi.org/10.1016/j.tetasy.2007.07.003
by applicantGB910321
 US4493829
 EP0243322
 EP0939083
 US2001031748
 WO2006021843
    - CREMONESI P ET AL., ARZNEIMITTEL-FORSCHUNG, (1984), vol. 34, no. 9, page 948 952
    - REMONESI P ET AL., INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY, THERAPY, AND TOXICOLOGY, vol. 31, no. 1, pages 40 - 51
    - LAZZARI ET AL., CLINICAL DRUG INVESTIGATION, (2005), vol. 5, no. 11, pages 679 - 689
    - TETRAHEDRON: ASYMMETRY, (2007), vol. 18, pages 1625 - 1627
    - "Iron derivatives of modified milk protein", ARZNEIMITTEL-FORSCHUNG, (1984), vol. 34, no. 9, pages 948 - 952
    - INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY, THERAPY, AND TOXICOLOGY, (199901), vol. 31, no. 1, pages 40 - 51
    - "Overview of clinical trials in the treatment of iron deficiency with iron acetyl-aspartylated casein", CLINICAL DRUG INVESTIGATION, (2005), vol. 2, no. 11, pages 679 - 689
    - TETRAHEDRON: ASYMMETRY, (2007), vol. 18, pages 1625 - 27
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.